GSK 4396687A
Alternative Names: GSK-4396687; GSK-4396687ALatest Information Update: 13 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 13 Nov 2023 Phase-II clinical trials in COVID-2019 infections (In adolescents, In adults, In the elderly, Prevention) (parenteral) (GSK pipeline, November 2023)
- 29 Apr 2022 Phase-I clinical trials in COVID-2019 infections (In adults, In the elderly, Prevention, In adolescents) in United Kingdom (Parenteral), prior to April 2022 (GlaxoSmithKline pipeline, April 2022)